Goldman Sachs Invests $150M in Aidoc: Revolutionizing Diagnostic Errors with AI
Aidoc, a clinical AI company founded in Israel and widely used worldwide, has raised $150 million in a Series E round led by Goldman Sachs Alternatives’ Growth Equity. This significant investment is expected to fuel Aidoc’s mission to reduce diagnostic errors in hospitals using AI-powered solutions.
What is Aidoc and How Does it Work?
Aidoc was founded in 2016 by Elad Walach, who is also the CEO. The company has focused on building both regulatory credibility and new technology, which has given Aidoc a strong advantage in the market. Aidoc’s CARE foundation model works with various imaging modalities, such as CT and X-ray, and runs on its aiOS platform, which connects directly to hospital systems.
The platform has reviewed more than 110 million patient cases in almost 2,000 hospitals, helping doctors make decisions for about 60 million patients each year. This impressive track record has caught the attention of investors, including Goldman Sachs, General Catalyst, SoftBank Vision Fund 2, and NVentures, Nvidia’s venture capital arm.
Competition in the Clinical AI Space
There is strong competition in the clinical AI space, with companies like Viz.ai, Nuance, Rad AI, and Subtle Medical focusing on different areas of radiology and imaging. Viz.ai raised $100 million in 2022 and focuses on AI for stroke and heart conditions. Nuance, which is now part of Microsoft, leads in radiology reporting with Dragon Medical. Rad AI creates AI-generated radiology reports, and Subtle Medical works on improving imaging quality.
However, Aidoc maintains that it operates a single platform that manages multiple AI tools across the entire imaging workflow, and is better positioned than point solutions that require separate integrations for each disease area.
Goldman Sachs’ Investment and Aidoc’s Future Plans
The $150 million investment will help Aidoc cover more diseases and build automated draft-reporting features within the next 2 years. This investment is a significant vote of confidence in Aidoc’s technology and its potential to revolutionize the healthcare industry.
“Aidoc pairs advanced technology with regulatory rigour in a way that few companies have achieved. Health systems consistently describe tangible results, including improved radiology efficiency, shorter lengths of stay, and measurable financial returns. We believe this combination of innovation, safety, technical rigour, and operational discipline positions Aidoc as a long-term leader in clinical AI,” says Christian Resch, Partner at Growth Equity at Goldman Sachs Alternatives.
Implications for Indian Investors and the Healthcare Industry
The investment in Aidoc has significant implications for Indian investors and the healthcare industry. As the Indian healthcare industry continues to grow and evolve, there is a growing need for innovative solutions that can improve patient outcomes and reduce diagnostic errors.
Indian investors who are interested in the healthcare technology space can consider investing in companies like Pharmaceutical stocks or Healthcare technology stocks. These investments can provide a unique opportunity to be a part of the growing healthcare industry and potentially generate significant returns.
Conclusion
In conclusion, the investment in Aidoc by Goldman Sachs is a significant development in the clinical AI space. Aidoc’s innovative technology and strong track record have made it a leader in the industry, and this investment is expected to fuel its continued growth and innovation.
As the Indian healthcare industry continues to evolve, it is likely that we will see more investments in healthcare technology companies like Aidoc. Indian investors who are interested in this space should consider doing their research and potentially investing in these companies to be a part of the growing healthcare industry.